NVS - Novartis AG
| Previous close | 87.23 |
| Open | 86.54 |
| Bid | 86.46 x 800 |
| Ask | 86.85 x 800 |
| Day's range | 86.36 - 86.92 |
| 52-week range | 73.54 - 95.00 |
| Volume | 992,171 |
| Avg. volume | 1,786,118 |
| Market cap | 198.006B |
| Beta (3Y monthly) | 0.54 |
| PE ratio (TTM) | 17.85 |
| EPS (TTM) | 4.87 |
| Earnings date | N/A |
| Forward dividend & yield | 2.83 (3.26%) |
| Ex-dividend date | 2019-03-04 |
| 1y target est | 101.00 |
- Zacks
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
- Zacks
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
- Zacks
Roche Posts Solid Sales for First 9 Months of '19, Ups View
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
- Zacks
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
- Zacks
Roche Announces Positive Late-Stage Data on Rituxan in PV
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
- Zacks
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval
Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.
- Zacks
Is Novartis (NVS) Outperforming Other Medical Stocks This Year?
Is (NVS) Outperforming Other Medical Stocks This Year?
- Zacks
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
- Zacks
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
- Zacks
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
- Zacks
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
- Zacks
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
- Zacks
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
- Zacks
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali
Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
- Zacks
Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
- Zacks
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
- Zacks
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
- Zacks
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
- Zacks
Here's Why AstraZeneca (AZN) is Outperforming Its Industry
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
- Zacks
Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
- Zacks
Incyte Treats First Patient in Phase III Vitiligo Study
Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
- Zacks
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
- Reuters
Novartis blames former AveXis executives for Zolgensma data manipulation
Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so. The Kaspar brothers were executives at AveXis, the company that developed the drug and was acquired by Novartis for $8.7 billion last year. Last month, the U.S. Food and Drug Administration said Novartis could face civil or criminal penalties because of the data manipulation and the possibility the company had waited to notify regulators.
